Evidence map›Paper›PMID 40056232›Full record

ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2025

[Potential and limitations of school vaccination programs to increase HPV vaccination rates in Germany].

Anja Takla, Nora Schmid-Küpke, Ole Wichmann

Abstract readEnglish AbstractReview
In one paragraph

Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Vaccine prevention of HPV-associated diseases].Dermatologie (Heidelberg, Germany) · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anja TaklaFachgebiet Impfprävention, STIKO, Abteilung für Infektionsepidemiologie, Robert Koch-Institut, Berlin, Deutschland. TaklaA@rki.de.
Nora Schmid-KüpkeFachgebiet Impfprävention, STIKO, Abteilung für Infektionsepidemiologie, Robert Koch-Institut, Berlin, Deutschland.
Ole WichmannFachgebiet Impfprävention, STIKO, Abteilung für Infektionsepidemiologie, Robert Koch-Institut, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even more than 15 years after the first vaccination recommendation by the Standing Committee on Vaccination (STIKO) against human papillomaviruses (HPV), vaccination coverage in Germany remains low. As a possible measure to increase HPV vaccination coverage in Germany, the widespread introduction of HPV school vaccination programs, as they exist in other European countries, is often called for. However, any implementation of a widespread health intervention should be preceded by an evidence assessment that also takes national circumstances into account. This article provides an overview of the evidence available to date on the effect of school vaccination programs in Germany and discusses the results. Corresponding evidence is so far limited and comes from three local (pilot) programs. These show that about one-third of those not vaccinated took up the school vaccination offer, while two-thirds did not. No program in Germany has yet collected data on the reasons for not accepting the vaccination offer or whether any hesitancy that may exist relates to the place of vaccination (school) or the vaccination itself. Furthermore, there is a lack of cost-benefit analyses of school vaccination programs. This would be important for their evaluation due to the structures that would have to be newly established in Germany for this purpose. Based on the evidence available to date, it seems rather unlikely that the introduction of a comprehensive school vaccination program could significantly increase HPV vaccination rates in Germany. However, in addition to other measures, school vaccination programs could possibly be part of a structured vaccination system for specific target groups or in certain defined regions. In contrast to the existing vaccination system in Germany, such a structured vaccination system could ensure that all members of the target group are actively offered HPV vaccination.

Indexed as

Immunization ProgramsMass VaccinationPapillomavirus InfectionsPapillomavirus VaccinesSchool Health ServicesUterine Cervical NeoplasmsVaccinationVaccination CoverageAdolescentChildFemaleGermanyHumansMalePapillomavirus VaccinesEvidence-basedHPV vaccinationImmunization systemsImplementationSchool vaccination

Identifiers

PMID40056232
PMCPMC11950032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.